Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulixertinib and Palbociclib in Advanced Solid Tumors, Pancreatic Cancer, and Melanoma
NCT03454035Phase 1Recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Jan 2018
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ulixertinib in solid tumor, pancreatic cancer (PC) and melanoma, sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoints: Maximum Tolerated Dose at 5 weeks and Overall Survival at 6 months. Started Jan 2018; status: recruiting.
02
Drugs
ulixertinib
03
Conditions
solid tumorpancreatic cancer (PC)melanoma
Beyond the preview
Go deeper on NCT03454035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03454035.